Pure Global AI
NCT06364501Not yet recruiting

Phase 1 Trial of KH801

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Anti-tumor Activity of KH801 Injection in Patients With Advanced Solid Tumors
Beijing Kanghong Biopharmaceutical Co., Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Advanced Solid Tumors
Drug/Device/Intervention
KH801
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Beijing Kanghong Biopharmaceutical Co., Ltd.
Funder
Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Location
Peking,Guangzhou,Jinan,Chengdu, China
Timeline & enrollment
Phase
Phase 1
Start date
May 01, 2024
End date
May 01, 2030
Enrollment
17 participants
Primary outcome

MTD,DLT,RP2D

Summary

KH801 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Or
 0.9% sodium chloride Injection.
 
 This study is expected to include a total of approximately 17-42 participants.

ICD-10 classifications
Malignant neoplasm: PrepuceCarcinoma in situ, unspecifiedMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm: Orbit
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06364501
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06364501 through Pure Global AI's free database. This Phase 1 trial is sponsored by Beijing Kanghong Biopharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 17 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.